GLUE - Monte Rosa Corp Enterprise Value

Monte Rosa Therapeutics (GLUE) develops targeted therapies against tumors. This chart on GURU.Markets illustrates an Enterprise Value of 310.97. The company's success is based on the authority of its leadership, which creates transparent protein degradation systems, and partnerships with industry behemoths. Meanwhile, the startup's operations rely on a laboratory work format with strict control over chemical waste disposal.

GLUE (Monte Rosa Therapeutics) Total Company Value history from 11/23/2025 to 10/27/2026

Monte Rosa Therapeutics - analytical breakdowns and key metrics (GLUE)

- price and consensus price forecast:

Price Chart Monte Rosa Therapeutics Inc|GLUE - Consensus Target

- market capitalization data:

Market Capitalization Monte Rosa Therapeutics|GLUE - Enterprise Value

- book capitalization data:

Net Asset Value per Share Monte Rosa Therapeutics|GLUE - Company Book Value|Market-to-Book Ratio monterosatx.com|GLUE - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio Monte Rosa Therapeutics|GLUE - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio monterosatx.com|GLUE - Company Debts|Debts to Book Value Monte Rosa Therapeutics

Fundamental valuation:Monte Rosa Therapeutics Inc (GLUE)

Original product of Monte Rosa Therapeutics, Inc.

Enterprise value is determined by the sum of market capitalization and net debt, which allows for an assessment of the actual costs of a full business buyout accounting for liquid assets. For Monte Rosa Therapeutics (GLUE), this metric reflects the market value of its unique protein degradation technologies; therefore, the historical enterprise value trend serves as an indicator of the investment attractiveness of its scalable cancer therapy.

Competitors of Monte Rosa Therapeutics (GLUE)